MX2017016719A - Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. - Google Patents
Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.Info
- Publication number
- MX2017016719A MX2017016719A MX2017016719A MX2017016719A MX2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A MX 2017016719 A MX2017016719 A MX 2017016719A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- formation
- prevent
- advanced glycation
- carboxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Molecular Biology (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica, fisicoquímicamente estable, en una unidad de dosis caracterizada porque comprende cantidades efectivas de los principios activos tiamina (Vitamina B1), piridoxina (Vitamina B6), un fiavonoide como la quercetina y un polifenol como la curcumina, o sus sales farmacéuticamente aceptables en combinación con excipientes farmacéuticamente aceptables, para la prevención de la formación y/o atrapamiento de los productos finales de la glicación avanzada (glioxal, metilglioxal, N-carboxi-metil-Iisina, N-carboxi-etil-lisina, pirralina, pentosidina, dímero de lisina, etc), que puede ser empleada en el tratamiento y/o prevención de las complicaciones de la diabetes mellitus (neuropatía, nefropatía y retinopatía diabética). La composición farmacéutica de la invención se presenta en forma oral, preferentemente en cápsula, tableta o sobre para administración oral.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017016719A MX2017016719A (es) | 2017-12-19 | 2017-12-19 | Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. |
US16/108,239 US11406636B2 (en) | 2017-12-19 | 2018-08-22 | Combined pharmaceutical composition |
US17/818,058 US20220370449A1 (en) | 2017-12-19 | 2022-08-08 | Combined pharmaceutical composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017016719A MX2017016719A (es) | 2017-12-19 | 2017-12-19 | Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016719A true MX2017016719A (es) | 2020-01-20 |
Family
ID=66815452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016719A MX2017016719A (es) | 2017-12-19 | 2017-12-19 | Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. |
Country Status (2)
Country | Link |
---|---|
US (2) | US11406636B2 (es) |
MX (1) | MX2017016719A (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020236622A1 (en) * | 2019-05-17 | 2020-11-26 | Trustees Of Tufts College | Compositions and methods for preventing inflammatory conditions |
JP7501832B2 (ja) * | 2019-07-31 | 2024-06-18 | ハウス食品株式会社 | グルコース酸化物生成抑制用組成物、AGEs生成抑制用組成物、及び、AGEsを介したタンパク質分子間の架橋の切断用組成物 |
CA3200072A1 (en) * | 2020-12-17 | 2022-06-23 | Majeed, Muhammed | Compositions for effective management of fibroblast-like synoviocytes m ediated rheumatoid arthritis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070059378A1 (en) * | 2001-02-02 | 2007-03-15 | Metagenics, Inc. | Medical composition for balancing bodily processes |
TW200613009A (en) * | 2004-06-11 | 2006-05-01 | Ono Pharmaceutical Co | Capsule having chewing stability |
US20080044390A1 (en) * | 2006-08-11 | 2008-02-21 | Xiaowei Jin | Methods and compositions for the treatment of neurodegenerative disorders |
US20130071525A1 (en) * | 2010-03-29 | 2013-03-21 | Kaneka Corporation | Coating fat composition and particulate composition using the same |
WO2014160423A1 (en) * | 2013-03-13 | 2014-10-02 | Genetic Disease Investigators, LLC | Methods and compositions for correction of organ dysfunction |
WO2016179097A1 (en) | 2015-05-04 | 2016-11-10 | Stella Maris | Methods for treating mitochondrial damage diseases |
-
2017
- 2017-12-19 MX MX2017016719A patent/MX2017016719A/es unknown
-
2018
- 2018-08-22 US US16/108,239 patent/US11406636B2/en active Active
-
2022
- 2022-08-08 US US17/818,058 patent/US20220370449A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190183892A1 (en) | 2019-06-20 |
US11406636B2 (en) | 2022-08-09 |
US20220370449A1 (en) | 2022-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016719A (es) | Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. | |
CO6210803A2 (es) | Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel | |
AR078812A1 (es) | Preparacion que comprende aminoacidos y plantas y su actividad en la detoxificacion del alcohol | |
JP2019517542A5 (es) | ||
RU2017119230A (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
IL254641B2 (en) | Methods and preparations including naproxen and fexofenamide for relieving symptoms of dizziness associated with alcohol consumption | |
JP2010540566A5 (es) | ||
JP2011513340A5 (es) | ||
Roopashri et al. | Radiotherapy and chemotherapy induced oral mucositis--prevention and current therapeutic modalities | |
WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
MX2019014687A (es) | Formulaciones farmaceuticas orales de remogliflozina. | |
Morazzoni et al. | SAMITAL®: a new botanical drug for the treatment of mucositis induced by oncological therapies | |
WO2007144081A3 (de) | Raucherentwöhnungs-kombinationswafer | |
MX2015013330A (es) | Composicion farmaceutica combinada para la prevencion de las complicaciones de la diabetes mellitus. | |
US20210401915A1 (en) | Compositions and methods for the management of mucositis in mammals | |
US20220323535A1 (en) | Health supplement | |
JP2014129321A5 (es) | ||
WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
Cheruvu et al. | (428) Single-and multiple-dose pharmacokinetics of extended-release hydrocodone bitartrate/acetaminophen tablets (MNK-155) with a loading dose of 3 tablets followed by 2 tablets administered q12h compared with immediate-release hydrocodone bitartrate and acetaminophen tablets | |
Devarakonda et al. | (431) Single-and multiple-dose pharmacokinetics of extended-release hydrocodone bitartrate/acetaminophen tablets (MNK-155) with and without loading dose compared with marketed immediate-release hydrocodone bitartrate/acetaminophen tablets | |
Singla et al. | (429) Randomized, double-blind, placebo-controlled, phase 3 study of the safety and analgesic efficacy of MNK-155 extended-release hydrocodone bitartrate/acetaminophen tablets (HB/APAP ER) in an acute pain model | |
RU2739187C2 (ru) | Комплексное средство для облегчения похмельного синдрома и гепатопротекторного действия | |
RU2580290C2 (ru) | Фармацевтическая композиция лекарственного средства седативного и спазмолитического действия в форме мягких желатиновых капсул (варианты) | |
CN106890216B8 (zh) | 一种治疗慢性咽炎的药物组合物及其制备方法、制剂与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: GIDD COMMERCIAL USA, INC. |